Literature DB >> 1984457

The human antibody response to streptococcal C5a peptidase.

S P O'Connor1, D Darip, K Fraley, C M Nelson, E L Kaplan, P P Cleary.   

Abstract

An ELISA was developed to measure antibody, both IgG and IgA, against the streptococcal C5a peptidase (SCP), in human sera and saliva. Generally, sera and saliva from young, uninfected children lacked antibody to SCP. In contrast, most sera and saliva specimens from healthy adults had measurable levels of anti-SCP IgG and SCP-specific secretory IgA (anti-SCP sIgA). Paired acute and convalescent sera from patients with streptococcal pharyngitis possessed significantly higher levels of anti-SCP IgG than did sera from healthy individuals. Sera containing high concentrations of anti-SCP immunoglobulin were capable of neutralizing SCP activity. A survey of healthy adults and children also showed that the latter were significantly less likely to have anti-SCP sIgA in their saliva. Detection of this antibody in greater than 90% of the saliva specimens obtained from children who had recently experienced streptococcal pharyngitis demonstrated that children can produce a secretory response. This is thought to be the first report of a secretory IgA response in humans to a somatic antigen of Streptococcus pyogenes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984457     DOI: 10.1093/infdis/163.1.109

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci.

Authors:  P P Cleary; J Peterson; C Chen; C Nelson
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

2.  Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.

Authors:  Hae-Sun Park; P Patrick Cleary
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 3.  Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.

Authors:  Gunnar Lindahl; Margaretha Stålhammar-Carlemalm; Thomas Areschoug
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus.

Authors:  Y Ji; B Carlson; A Kondagunta; P P Cleary
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 5.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

6.  Vaccine strategies to prevent rheumatic fever.

Authors:  E R Brandt; M F Good
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

7.  Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci.

Authors:  E R Brandt; W A Hayman; B Currie; J Carapetis; Y Wood; D C Jackson; J Cooper; W D Melrose; A J Saul; M F Good
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

8.  Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis.

Authors:  S M Kuhn; J Preiksaitis; G J Tyrrel; T Jadavji; D Church; H D Davies
Journal:  Can J Infect Dis       Date:  2001-01

9.  Ubiquitous occurrence of virR and scpA genes in group A streptococci.

Authors:  A Podbielski
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 10.  Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.

Authors:  Shu Ki Tsoi; Pierre R Smeesters; Hannah R C Frost; Paul Licciardi; Andrew C Steer
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.